NCT03432364 - A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 29, 2018

Primary Completion Date

November 17, 2022

Study Completion Date

November 17, 2022

Conditions

Transfusion Dependent Beta-thalassemia

Interventions

GENETIC

ST-400 Investigational product

Single dose of ST-400 following chemotherapy conditioning with busulfan

Trial Locations (6)

Children's Hospital of Philadelphia, Philadelphia

Children's Healthcare of Atlanta, Atlanta

University of Minnesota, Minneapolis

UCSF Benioff Children's Hospital Oakland, Oakland

University of California, Los Angeles, Los Angeles

Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston